Loading clinical trials...
Loading clinical trials...
This study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active systemic juvenile idiopathic arthritis (sJIA) who have an inadequate clinical response to NS...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hoffmann-La Roche
NCT05609630 · Juvenile Idiopathic Arthritis
NCT06838143 · Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), and more
NCT06870045 · Juvenile Idiopathic Arthritis, Childhood Rheumatic Disease
NCT05534347 · Juvenile Idiopathic Arthritis (JIA)
NCT04902807 · Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia, and more
Little Rock, Arkansas
Los Angeles, California
Hartford, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions